Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).
About this study
Radiochemotherapy is the standard treatment for neoplasms of the anal canal with excellent rates of local control and preservation of the anal sphincter. However, patients may experience a deterioration of quality of life related to sequelae of the treatment particularly at intestinal, anal sphincter and sexual level. Few studies to date have documented patient-reported outcomes (PROs) in this area. The aim of this observational study is to verify the quality of life (QOL) of the patients by means of self-completed questionnaires.
- Condition
- Anal Cancer Patients
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Study condition: Anal Cancer Patients
- Eastern Cooperative Oncology Group (ECOG) 0-3
- minimum 18 years old
- squamous cell carcinoma of the anal canal
- low burden of metastatic disease at diagnosis
- indication for radiochemotherapy treatment
- informed consent
Exclusion 3
- age under 18 years
- Eastern Cooperative Oncology Group (ECOG) higher than 3
- metastatic disease at diagnosis not amenable to radiochemotherapy treatment
Where
1 site, 1 recruiting
Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome, Lazio, Italy
Contact
-
Stefania Manfrida, MD
0039 0630154434 stefania.manfrida@policlinicogemelli.it
-
Stefania Manfrida
+390630155701 stefania.manfrida@policlinicogemelli.it
Potential match only. Final eligibility is determined by the study team.